Summit plc CEO pleased with drug development progress - Summit plcs (LON:SUMM) chief executive, Glyn Edwards, says the key element to the half-year results is the great progress made in the drug development groups two clinical programmes. He says he is pleased to have strengthened the company both financially - having raised 22mln in March - and operationally. Edwards speaks about the US expansion and plans for the second half of the year. ow.ly/2MUP3j
Posted on: Thu, 04 Sep 2014 11:10:57 +0000